vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Sachem Capital Corp. (SACH). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $12.0M, roughly 1.6× Sachem Capital Corp.). Sachem Capital Corp. runs the higher net margin — 8.3% vs -0.8%, a 9.1% gap on every dollar of revenue. On growth, Sachem Capital Corp. posted the faster year-over-year revenue change (-18.8% vs -25.7%). Over the past eight quarters, Sachem Capital Corp.'s revenue compounded faster (-13.4% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Sachem Capital Corp.SACHEarnings & Financial Report
Sachem Head Capital Management is an American value-oriented investment management firm based in New York City, managed by Scott Ferguson.
CTMX vs SACH — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $12.0M |
| Net Profit | $-154.0K | $997.0K |
| Gross Margin | — | — |
| Operating Margin | -6.9% | -3.1% |
| Net Margin | -0.8% | 8.3% |
| Revenue YoY | -25.7% | -18.8% |
| Net Profit YoY | 97.6% | 119.7% |
| EPS (diluted) | — | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $12.0M | ||
| Q2 25 | $18.7M | $10.8M | ||
| Q1 25 | $50.9M | $11.4M | ||
| Q4 24 | $38.1M | $10.8M | ||
| Q3 24 | $33.4M | $14.8M | ||
| Q2 24 | $25.1M | $15.1M | ||
| Q1 24 | $41.5M | $16.8M | ||
| Q4 23 | $26.6M | $16.0M |
| Q3 25 | — | $997.0K | ||
| Q2 25 | $-154.0K | $1.9M | ||
| Q1 25 | $23.5M | $904.0K | ||
| Q4 24 | $18.9M | $-36.1M | ||
| Q3 24 | $5.7M | $-5.1M | ||
| Q2 24 | $-6.5M | $-3.1M | ||
| Q1 24 | $13.8M | $4.7M | ||
| Q4 23 | $837.0K | $-1.1M |
| Q3 25 | — | -3.1% | ||
| Q2 25 | -6.9% | 9.9% | ||
| Q1 25 | 44.4% | 9.0% | ||
| Q4 24 | 46.4% | -131.1% | ||
| Q3 24 | 12.3% | -32.6% | ||
| Q2 24 | -33.7% | -20.6% | ||
| Q1 24 | 28.1% | 25.4% | ||
| Q4 23 | -2.3% | — |
| Q3 25 | — | 8.3% | ||
| Q2 25 | -0.8% | 17.5% | ||
| Q1 25 | 46.2% | 7.9% | ||
| Q4 24 | 49.6% | -335.6% | ||
| Q3 24 | 17.2% | -34.2% | ||
| Q2 24 | -26.0% | -20.2% | ||
| Q1 24 | 33.3% | 27.8% | ||
| Q4 23 | 3.1% | -6.9% |
| Q3 25 | — | $0.00 | ||
| Q2 25 | — | $0.02 | ||
| Q1 25 | — | $0.00 | ||
| Q4 24 | — | $-0.79 | ||
| Q3 24 | — | $-0.13 | ||
| Q2 24 | — | $-0.09 | ||
| Q1 24 | — | $0.08 | ||
| Q4 23 | — | $-0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $12.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $175.6M |
| Total Assets | $175.1M | $484.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $12.6M | ||
| Q2 25 | $49.0M | $23.5M | ||
| Q1 25 | $47.6M | $25.8M | ||
| Q4 24 | $38.1M | $19.6M | ||
| Q3 24 | $40.6M | $7.4M | ||
| Q2 24 | $43.2M | $12.4M | ||
| Q1 24 | $36.2M | $56.8M | ||
| Q4 23 | $17.2M | $50.4M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $230.2M | ||
| Q4 24 | — | $230.2M | ||
| Q3 24 | — | $264.7M | ||
| Q2 24 | — | $264.7M | ||
| Q1 24 | — | $288.4M | ||
| Q4 23 | — | $288.4M |
| Q3 25 | — | $175.6M | ||
| Q2 25 | $119.9M | $177.9M | ||
| Q1 25 | $25.0M | $179.3M | ||
| Q4 24 | $-456.0K | $181.7M | ||
| Q3 24 | $-23.5M | $220.6M | ||
| Q2 24 | $-31.2M | $230.2M | ||
| Q1 24 | $-31.7M | $237.4M | ||
| Q4 23 | $-47.4M | $230.1M |
| Q3 25 | — | $484.4M | ||
| Q2 25 | $175.1M | $501.8M | ||
| Q1 25 | $98.5M | $491.4M | ||
| Q4 24 | $120.5M | $492.0M | ||
| Q3 24 | $139.0M | $555.5M | ||
| Q2 24 | $159.2M | $586.3M | ||
| Q1 24 | $184.7M | $626.5M | ||
| Q4 23 | $201.8M | $620.9M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.28× | ||
| Q4 24 | — | 1.27× | ||
| Q3 24 | — | 1.20× | ||
| Q2 24 | — | 1.15× | ||
| Q1 24 | — | 1.21× | ||
| Q4 23 | — | 1.25× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $4.9M |
| Free Cash FlowOCF − Capex | $-15.8M | — |
| FCF MarginFCF / Revenue | -84.6% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | 4.95× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $4.9M | ||
| Q2 25 | $-15.8M | $501.0K | ||
| Q1 25 | $-21.0M | $191.0K | ||
| Q4 24 | $-19.9M | $12.9M | ||
| Q3 24 | $-20.7M | $2.3M | ||
| Q2 24 | $-19.5M | $7.0M | ||
| Q1 24 | $-26.0M | $4.2M | ||
| Q4 23 | $-22.0M | $2.9M |
| Q3 25 | — | — | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | — | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.6M | — | ||
| Q1 24 | $-26.2M | — | ||
| Q4 23 | $-22.2M | — |
| Q3 25 | — | — | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | — | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | — | ||
| Q2 24 | -78.2% | — | ||
| Q1 24 | -63.1% | — | ||
| Q4 23 | -83.5% | — |
| Q3 25 | — | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.3% | — | ||
| Q4 23 | 1.0% | — |
| Q3 25 | — | 4.95× | ||
| Q2 25 | — | 0.27× | ||
| Q1 25 | -0.89× | 0.21× | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | 0.90× | ||
| Q4 23 | -26.24× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
SACH
Segment breakdown not available.
